NFE2L2 and cancer: Collectively, these results provide proof-of-principle evidence that the pharmacologic suppression of NFE2L2-linked transcriptional programs, particularly by rosiglitazone, can partially re-sensitize drug-resistant cancer cells, reinforcing the predictive validity of our computational screening pipeline.